Racial and ethnic disparities are apparent among Black patients with pulmonary fibrosis (PF), including earlier onset of death, according to a recent study.
In a study on racial and ethnic disparities in patients with pulmonary fibrosis (PF), Black patients were found to be younger at the time of diagnosis, hospitalization, and death than White patients.
The results of this cohort study were published in JAMA Network Open.1
Pulmonary fibrosis is a disease that kills up to half of patients within 5 years of diagnosis. Despite such devastating outcomes, little is known about what racial and ethnic disparities exist.
The study sought to test the hypothesis that the age at clinically relevant outcomes (diagnosis, hospitalization, lung transplant, and death) in PF differs by racial or ethnic category.
Researchers included a total of 4792 participants with a diagnosis of PF from prospective clinical registries, the Pulmonary Fibrosis Foundation Registry (PFFR), and from 4 external multicenter validation (EMV) cohorts in the United States from January 2003 to April 2021.
From the cohorts, 2779 (58%) were male, 488 (10.2%) Black, 319 (6.7%) Hispanic, and 3985 (83.2%) White. Additionally, 1904 patients were in the PFFR cohort and 2888 were in the EMV cohort.
The researchers found that Black patients were diagnosed with PF at an average age of 57.9 years, while White patients were diagnosed at an average age of 68.6 years.
Black patients were also less likely to be male (PFFR, 30.5%; EMV, 26.6%) than Hispanic (PFFR, 58.9%; EMV, 55.9%) and White (PFFR, 30.5%; EMV, 59.4%) patients, and more likely to be hospitalized, with a mean standard deviation (SD) hospitalization per person (PFFR: Black, 3.6 [5.0]; Hispanic, 1.8 [1.4]; White, 1.7 [1.3]; P <.001; EMV: Black, 2.6 [2.2]; Hispanic, 1.9 [1.7]; White, 1.8 [1.4]; P <.001).
Black patients were also younger than Hispanic or White patients at the time of initial hospitalization (mean SD age: Black, 59.4 [11.7] years; Hispanic, 67.5 [9.8] years; White, 70 [9.3] years; P<.001), lung transplant (Black, 58.6 [8.6] years; Hispanic, 60.5 [6.1] years; White, 66.9 [6.7] years; P<.001), and death (Black, 68.7 [8.4] years; Hispanic, 72.9 [7.6] years; White, 73.5 [8.7] years; P <.001).
Furthermore, PF was linked to risk factors, such as rheumatoid arthritis, exposure to air pollution, and occupations that make an individual at high risk of inhaling particulate matter and smoking.
The researchers believe that the disparities are likely attributed to lifestyle and socioeconomic factors that disproportionately place Black patients at higher risk of environmental exposures. These results remained consistent in the replication cohort and sensitivity analysis within age groups.
“This disease has no clear cause and no cure, but it is not a cancer; the poor prognosis made me wonder if Black patients are as affected by this disease as whites [patients], and whether or not they experienced different outcomes,” said Ayodeji Adegunsoye, MD, MS, assistant professor at the University of Chicago Medicine, and study’s lead author, in a statement.1 “And we saw that Black patients’ experience with the disease is accelerated by about 10 years.”
The researchers also believe that racial disparities may be associated with earlier onset of PF outcomes, especially among Black patients. Furthermore, these results highlight a need for policy changes to bring attention to environmental and societal risks that are disproportionately affecting Black patients.
“These results are so profound that I believe we should be screening everyone for pulmonary fibrosis earlier, especially if a patient has any risk factors,” said Adegunsoye. “If you can pick up the disease sooner, the outcomes will improve. We know more about the disease now than we did even 10 years ago, and while there is no cure, there are treatments available — some of them are as simple as changing your environment or wearing a mask to reduce environmental exposure, but there are also drugs that can slow the progression of the disease.”
References
1. UChicagoMed. Black patients are diagnosed with, hospitalized for and die of pulmonary fibrosis at younger ages than white patients. University of Chicago. https://www.eurekalert.org/news-releases/982398. Published March 10, 2023. Accessed March 27, 2023.
2. Adegunsoye A, Freiheit E, White EN, et al. Evaluation of pulmonary fibrosis outcomes by race and ethnicity in US adults. JAMA Netw Open. 2023;6(3). doi:10.1001/jamanetworkopen.2023.2427
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More